[Use of intravenous immunoglobulins - a review of management strategy experiences and the available evidence]
Lance JM
Record ID 32014001344
French
Original Title:
Utilisation des immunoglobulines intraveineuses Revue des expériences de stratégies de gestion et des données probantes disponibles
Authors' recommendations:
IVIgs are an essential replacement therapy for primary and secondary immune deficiencies, in which their use is officially approved by health authorities. The large remaining share of the use mainly concerns neurological indications and in hematology. However, IVIg use is also increasing rapidly in rheumatology and dermatology.
These latter indications, most of which are not officially authorized, can be divided into three categories: "well-recognized" (proven efficacy), "potential" (probable effect according to the available evidence) and "uncertain" (insufficient data). Since the well-recognized indications are few in number, clinical research is faced with major challenges to justify, with more solid evidence, the other uses, especially since they often concern rare diseases. Whatever the case, it is up to the professional associations and medical societies concerned to develop and update as rigorously and consensually as possible IVIg utilization guidelines based on the best available evidence. Neurological indications are emerging as a prime target.
As much as possible, continued clinical research will help clarify the most relevant indications for IVIg use and the most appropriate methods of administration. Because of the economic impact of the high cost of Igs, it would be advisable to closely examine the available treatment options to help choose one that is cost-effective.
Lastly, one should continue to explore the possibility of increasing the use of SCIgs, which could improve patient quality of life, while ensuring the safety of this approach.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Traitement/INESSS_Utilisation_immunoglobulines_intraveineuses.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Immunoglobulins
- Immunoglobulins, Intravenous
- Hematology
- Autoimmune Diseases
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
©Gouvernement du Québec/Institut national d'excellence en santé et en services sociaux
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.